The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014
Background and aims Pregnancy in women with systemic lupus erythematosus (SLE) is one of the challenges of recent studies. Women should prevent the onset of relapses with medications before and after pregnancy, and on the other hand, the effect of these medicines considers the health and development...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2019-11, Vol.38 (11), p.3211-3215 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3215 |
|---|---|
| container_issue | 11 |
| container_start_page | 3211 |
| container_title | Clinical rheumatology |
| container_volume | 38 |
| creator | Rajaei, Elham Shahbazian, Nahid Rezaeeyan, Hadi Mohammadi, Amal Kia Hesam, Saeed Zayeri, Zeinab Deris |
| description | Background and aims
Pregnancy in women with systemic lupus erythematosus (SLE) is one of the challenges of recent studies. Women should prevent the onset of relapses with medications before and after pregnancy, and on the other hand, the effect of these medicines considers the health and development of the fetus. In this retrospective study, the effects of anti-phospholipid syndrome and the use of common drugs such as methotrexate, cyclosporine, and azathioprine and their side effects on maternal health and ultimately the development of the fetus have been investigated.
Material and methods
This study is a descriptive and retrospective epidemiologic study that was conducted in 2016 to investigate maternal and fetal complications in SLE patients. We prepared forms of data recording, including age, occupation, and other important information and then analyzed them in SPSS version 22.
Result
The results showed that the presence of anti-phospholipid syndrome in pregnant women can lead to abnormalities such as preterm, IUGR, abortion, and fetal death (
P
value 0.0001). It also leads to complications such as nephritis, arthritis, and preeclampsia in the mother (
P
value 0.003). This study suggests that methotrexate and cyclosporine medications could cause fetal developmental disorders. The
P
value of cyclosporine was 0.0001 and the
P
value of methotrexate was 0.001.
Conclusion
Anti-phospholipid syndrome in women with SLE who intend to become pregnant can disrupt the development of the embryo. The consumption of methotrexate and cyclosporine medications before and during the pregnancy can have irreparable effects on fetal growth.
Key Points
•
Anti-phospholipid syndrome can disrupt the development of the embryo in women with SLE who intend to become pregnant
.
•
Methotrexate and cyclosporine consumption before and during pregnancy can affect fetal growth
.
•
7 to 33% of patients whose disease had been suppressed and controlled 6 months before pregnancy seams to relapse during the pregnancy
.
•
Taking medications to control the disease during pregnancy plays an important role in the progression of pregnancy and fetus health. |
| doi_str_mv | 10.1007/s10067-019-04682-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2266333885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2266333885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-d2ad2302df362eb06196f23a981d97ae7b804fc3d06957f619f68ce46f7452ad3</originalsourceid><addsrcrecordid>eNp9kT9vFDEQxS0EIpfAF6BAlmhoFsYer__QoQgIUiSaUFu-9ThcdLte7F2i-_b4uAASBY2neL_3PPZj7IWANwLAvK3t1KYD4TpQ2soOH7GNUKg655R7zDZgDHQonD1j57XeAYC0TjxlZyiwl1rpDUs334hTSjQsPCe-X-e18rirFCrxPPGlyXOh2ylMC7_PI008TJHTuC2HXN_xwAstJde5Bex-EK_LGg88lTxyCQL4ko9TPWNPUthXev4wL9jXjx9uLq-66y-fPl--v-4GNP3SRRmiRJAxoZa0BS2cThKDsyI6E8hsLag0YATtepOanLQdSOlkVN-8eMFen3Lnkr-vVBc_7upA-32YKK_VS6k1IlrbN_TVP-hdXsvUtjtSyjin0TZKnqihPbIWSn4uuzGUgxfgjy34Uwu-teB_teCxmV4-RK_bkeIfy-9vbwCegNqk6ZbK37v_E_sTtVOQPQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2264799638</pqid></control><display><type>article</type><title>The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Rajaei, Elham ; Shahbazian, Nahid ; Rezaeeyan, Hadi ; Mohammadi, Amal Kia ; Hesam, Saeed ; Zayeri, Zeinab Deris</creator><creatorcontrib>Rajaei, Elham ; Shahbazian, Nahid ; Rezaeeyan, Hadi ; Mohammadi, Amal Kia ; Hesam, Saeed ; Zayeri, Zeinab Deris</creatorcontrib><description>Background and aims
Pregnancy in women with systemic lupus erythematosus (SLE) is one of the challenges of recent studies. Women should prevent the onset of relapses with medications before and after pregnancy, and on the other hand, the effect of these medicines considers the health and development of the fetus. In this retrospective study, the effects of anti-phospholipid syndrome and the use of common drugs such as methotrexate, cyclosporine, and azathioprine and their side effects on maternal health and ultimately the development of the fetus have been investigated.
Material and methods
This study is a descriptive and retrospective epidemiologic study that was conducted in 2016 to investigate maternal and fetal complications in SLE patients. We prepared forms of data recording, including age, occupation, and other important information and then analyzed them in SPSS version 22.
Result
The results showed that the presence of anti-phospholipid syndrome in pregnant women can lead to abnormalities such as preterm, IUGR, abortion, and fetal death (
P
value 0.0001). It also leads to complications such as nephritis, arthritis, and preeclampsia in the mother (
P
value 0.003). This study suggests that methotrexate and cyclosporine medications could cause fetal developmental disorders. The
P
value of cyclosporine was 0.0001 and the
P
value of methotrexate was 0.001.
Conclusion
Anti-phospholipid syndrome in women with SLE who intend to become pregnant can disrupt the development of the embryo. The consumption of methotrexate and cyclosporine medications before and during the pregnancy can have irreparable effects on fetal growth.
Key Points
•
Anti-phospholipid syndrome can disrupt the development of the embryo in women with SLE who intend to become pregnant
.
•
Methotrexate and cyclosporine consumption before and during pregnancy can affect fetal growth
.
•
7 to 33% of patients whose disease had been suppressed and controlled 6 months before pregnancy seams to relapse during the pregnancy
.
•
Taking medications to control the disease during pregnancy plays an important role in the progression of pregnancy and fetus health.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-019-04682-3</identifier><identifier>PMID: 31352646</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Adult ; Antiphospholipid syndrome ; Arthritis ; Azathioprine ; Cyclosporins ; Developmental disabilities ; Embryos ; Epidemiology ; Female ; Fetal Development - drug effects ; Fetuses ; Health risk assessment ; Humans ; Immunosuppressive Agents - adverse effects ; Lupus ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - drug therapy ; Medicine ; Medicine & Public Health ; Methotrexate ; Nephritis ; Original Article ; Phospholipids ; Pre-eclampsia ; Pregnancy ; Pregnancy complications ; Pregnancy Complications - drug therapy ; Pregnancy Complications - etiology ; Retrospective Studies ; Rheumatology ; Studies ; Systemic lupus erythematosus ; Womens health ; Young Adult</subject><ispartof>Clinical rheumatology, 2019-11, Vol.38 (11), p.3211-3215</ispartof><rights>International League of Associations for Rheumatology (ILAR) 2019</rights><rights>Clinical Rheumatology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-d2ad2302df362eb06196f23a981d97ae7b804fc3d06957f619f68ce46f7452ad3</citedby><cites>FETCH-LOGICAL-c375t-d2ad2302df362eb06196f23a981d97ae7b804fc3d06957f619f68ce46f7452ad3</cites><orcidid>0000-0002-8621-5904</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-019-04682-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-019-04682-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27913,27914,41477,42546,51308</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31352646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rajaei, Elham</creatorcontrib><creatorcontrib>Shahbazian, Nahid</creatorcontrib><creatorcontrib>Rezaeeyan, Hadi</creatorcontrib><creatorcontrib>Mohammadi, Amal Kia</creatorcontrib><creatorcontrib>Hesam, Saeed</creatorcontrib><creatorcontrib>Zayeri, Zeinab Deris</creatorcontrib><title>The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Background and aims
Pregnancy in women with systemic lupus erythematosus (SLE) is one of the challenges of recent studies. Women should prevent the onset of relapses with medications before and after pregnancy, and on the other hand, the effect of these medicines considers the health and development of the fetus. In this retrospective study, the effects of anti-phospholipid syndrome and the use of common drugs such as methotrexate, cyclosporine, and azathioprine and their side effects on maternal health and ultimately the development of the fetus have been investigated.
Material and methods
This study is a descriptive and retrospective epidemiologic study that was conducted in 2016 to investigate maternal and fetal complications in SLE patients. We prepared forms of data recording, including age, occupation, and other important information and then analyzed them in SPSS version 22.
Result
The results showed that the presence of anti-phospholipid syndrome in pregnant women can lead to abnormalities such as preterm, IUGR, abortion, and fetal death (
P
value 0.0001). It also leads to complications such as nephritis, arthritis, and preeclampsia in the mother (
P
value 0.003). This study suggests that methotrexate and cyclosporine medications could cause fetal developmental disorders. The
P
value of cyclosporine was 0.0001 and the
P
value of methotrexate was 0.001.
Conclusion
Anti-phospholipid syndrome in women with SLE who intend to become pregnant can disrupt the development of the embryo. The consumption of methotrexate and cyclosporine medications before and during the pregnancy can have irreparable effects on fetal growth.
Key Points
•
Anti-phospholipid syndrome can disrupt the development of the embryo in women with SLE who intend to become pregnant
.
•
Methotrexate and cyclosporine consumption before and during pregnancy can affect fetal growth
.
•
7 to 33% of patients whose disease had been suppressed and controlled 6 months before pregnancy seams to relapse during the pregnancy
.
•
Taking medications to control the disease during pregnancy plays an important role in the progression of pregnancy and fetus health.</description><subject>Adult</subject><subject>Antiphospholipid syndrome</subject><subject>Arthritis</subject><subject>Azathioprine</subject><subject>Cyclosporins</subject><subject>Developmental disabilities</subject><subject>Embryos</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fetal Development - drug effects</subject><subject>Fetuses</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methotrexate</subject><subject>Nephritis</subject><subject>Original Article</subject><subject>Phospholipids</subject><subject>Pre-eclampsia</subject><subject>Pregnancy</subject><subject>Pregnancy complications</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Pregnancy Complications - etiology</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Studies</subject><subject>Systemic lupus erythematosus</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kT9vFDEQxS0EIpfAF6BAlmhoFsYer__QoQgIUiSaUFu-9ThcdLte7F2i-_b4uAASBY2neL_3PPZj7IWANwLAvK3t1KYD4TpQ2soOH7GNUKg655R7zDZgDHQonD1j57XeAYC0TjxlZyiwl1rpDUs334hTSjQsPCe-X-e18rirFCrxPPGlyXOh2ylMC7_PI008TJHTuC2HXN_xwAstJde5Bex-EK_LGg88lTxyCQL4ko9TPWNPUthXev4wL9jXjx9uLq-66y-fPl--v-4GNP3SRRmiRJAxoZa0BS2cThKDsyI6E8hsLag0YATtepOanLQdSOlkVN-8eMFen3Lnkr-vVBc_7upA-32YKK_VS6k1IlrbN_TVP-hdXsvUtjtSyjin0TZKnqihPbIWSn4uuzGUgxfgjy34Uwu-teB_teCxmV4-RK_bkeIfy-9vbwCegNqk6ZbK37v_E_sTtVOQPQ</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Rajaei, Elham</creator><creator>Shahbazian, Nahid</creator><creator>Rezaeeyan, Hadi</creator><creator>Mohammadi, Amal Kia</creator><creator>Hesam, Saeed</creator><creator>Zayeri, Zeinab Deris</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8621-5904</orcidid></search><sort><creationdate>20191101</creationdate><title>The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014</title><author>Rajaei, Elham ; Shahbazian, Nahid ; Rezaeeyan, Hadi ; Mohammadi, Amal Kia ; Hesam, Saeed ; Zayeri, Zeinab Deris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-d2ad2302df362eb06196f23a981d97ae7b804fc3d06957f619f68ce46f7452ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Antiphospholipid syndrome</topic><topic>Arthritis</topic><topic>Azathioprine</topic><topic>Cyclosporins</topic><topic>Developmental disabilities</topic><topic>Embryos</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fetal Development - drug effects</topic><topic>Fetuses</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methotrexate</topic><topic>Nephritis</topic><topic>Original Article</topic><topic>Phospholipids</topic><topic>Pre-eclampsia</topic><topic>Pregnancy</topic><topic>Pregnancy complications</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Pregnancy Complications - etiology</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Studies</topic><topic>Systemic lupus erythematosus</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rajaei, Elham</creatorcontrib><creatorcontrib>Shahbazian, Nahid</creatorcontrib><creatorcontrib>Rezaeeyan, Hadi</creatorcontrib><creatorcontrib>Mohammadi, Amal Kia</creatorcontrib><creatorcontrib>Hesam, Saeed</creatorcontrib><creatorcontrib>Zayeri, Zeinab Deris</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rajaei, Elham</au><au>Shahbazian, Nahid</au><au>Rezaeeyan, Hadi</au><au>Mohammadi, Amal Kia</au><au>Hesam, Saeed</au><au>Zayeri, Zeinab Deris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>38</volume><issue>11</issue><spage>3211</spage><epage>3215</epage><pages>3211-3215</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Background and aims
Pregnancy in women with systemic lupus erythematosus (SLE) is one of the challenges of recent studies. Women should prevent the onset of relapses with medications before and after pregnancy, and on the other hand, the effect of these medicines considers the health and development of the fetus. In this retrospective study, the effects of anti-phospholipid syndrome and the use of common drugs such as methotrexate, cyclosporine, and azathioprine and their side effects on maternal health and ultimately the development of the fetus have been investigated.
Material and methods
This study is a descriptive and retrospective epidemiologic study that was conducted in 2016 to investigate maternal and fetal complications in SLE patients. We prepared forms of data recording, including age, occupation, and other important information and then analyzed them in SPSS version 22.
Result
The results showed that the presence of anti-phospholipid syndrome in pregnant women can lead to abnormalities such as preterm, IUGR, abortion, and fetal death (
P
value 0.0001). It also leads to complications such as nephritis, arthritis, and preeclampsia in the mother (
P
value 0.003). This study suggests that methotrexate and cyclosporine medications could cause fetal developmental disorders. The
P
value of cyclosporine was 0.0001 and the
P
value of methotrexate was 0.001.
Conclusion
Anti-phospholipid syndrome in women with SLE who intend to become pregnant can disrupt the development of the embryo. The consumption of methotrexate and cyclosporine medications before and during the pregnancy can have irreparable effects on fetal growth.
Key Points
•
Anti-phospholipid syndrome can disrupt the development of the embryo in women with SLE who intend to become pregnant
.
•
Methotrexate and cyclosporine consumption before and during pregnancy can affect fetal growth
.
•
7 to 33% of patients whose disease had been suppressed and controlled 6 months before pregnancy seams to relapse during the pregnancy
.
•
Taking medications to control the disease during pregnancy plays an important role in the progression of pregnancy and fetus health.</abstract><cop>London</cop><pub>Springer London</pub><pmid>31352646</pmid><doi>10.1007/s10067-019-04682-3</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-8621-5904</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2019-11, Vol.38 (11), p.3211-3215 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2266333885 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Antiphospholipid syndrome Arthritis Azathioprine Cyclosporins Developmental disabilities Embryos Epidemiology Female Fetal Development - drug effects Fetuses Health risk assessment Humans Immunosuppressive Agents - adverse effects Lupus Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - drug therapy Medicine Medicine & Public Health Methotrexate Nephritis Original Article Phospholipids Pre-eclampsia Pregnancy Pregnancy complications Pregnancy Complications - drug therapy Pregnancy Complications - etiology Retrospective Studies Rheumatology Studies Systemic lupus erythematosus Womens health Young Adult |
| title | The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A37%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20lupus%20disease%20on%20the%20pregnant%20women%20and%20embryos:%20a%20retrospective%20study%20from%202010%20to%202014&rft.jtitle=Clinical%20rheumatology&rft.au=Rajaei,%20Elham&rft.date=2019-11-01&rft.volume=38&rft.issue=11&rft.spage=3211&rft.epage=3215&rft.pages=3211-3215&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-019-04682-3&rft_dat=%3Cproquest_cross%3E2266333885%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2264799638&rft_id=info:pmid/31352646&rfr_iscdi=true |